H.C. Wainwright analyst Raghuram Selvaraju upgraded MoonLake Immunotherapeutics (MLTX) to Buy from Neutral with a $30 price target The stock’s current valuation is not appropriate given the potential of sonelokimab, the analyst tells investors in a research note. The firm says that while the regulatory pathway is yet to be determined, existing precedent “seems encouraging.”
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MLTX:
- Buy/Sell: Wall Street’s top 10 stock calls this week
- MoonLake Immunotherapeutics downgraded to Sell from Neutral at Citi
- Moonlake Immunotherapeutics Advances Psoriatic Arthritis Treatment with Sonelokimab Study
- MoonLake Immunotherapeutics Advances with Promising Sonelokimab Study in Adolescents
- Moonlake Immunotherapeutics Advances in Hidradenitis Suppurativa Treatment with Sonelokimab Study